Market closed
ImmunityBio/$IBRX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About ImmunityBio
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
Ticker
$IBRX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
680
Website
ImmunityBio Metrics
BasicAdvanced
$2.5B
-
-$0.62
-0.18
-
Price and volume
Market cap
$2.5B
Beta
-0.18
52-week high
$10.53
52-week low
$2.28
Average daily volume
6.4M
Financial strength
Current ratio
3.36
Quick ratio
2.775
Long term debt to equity
-160.02
Total debt to equity
-161.805
Interest coverage (TTM)
-2.23%
Management effectiveness
Return on assets (TTM)
-48.48%
Return on equity (TTM)
77.02%
Valuation
Price to revenue (TTM)
139.986
Price to book
-5.16
Price to tangible book (TTM)
-5
Price to free cash flow (TTM)
-5.184
Growth
Revenue change (TTM)
2,270.58%
Earnings per share change (TTM)
-46.19%
3-year revenue growth (CAGR)
150.86%
3-year earnings per share growth (CAGR)
-11.44%
What the Analysts think about ImmunityBio
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for ImmunityBio stock.
ImmunityBio Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ImmunityBio Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ImmunityBio News
AllArticlesVideos
ImmunityBio to Host Investor Day
Business Wire·1 week ago
ImmunityBio: BCG Shortage And Tariff Risks Could Stifle Anktiva's Commercial Momentum
Seeking Alpha·4 weeks ago
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for ImmunityBio stock?
ImmunityBio (IBRX) has a market cap of $2.5B as of April 03, 2025.
What is the P/E ratio for ImmunityBio stock?
The price to earnings (P/E) ratio for ImmunityBio (IBRX) stock is 0 as of April 03, 2025.
Does ImmunityBio stock pay dividends?
No, ImmunityBio (IBRX) stock does not pay dividends to its shareholders as of April 03, 2025.
When is the next ImmunityBio dividend payment date?
ImmunityBio (IBRX) stock does not pay dividends to its shareholders.
What is the beta indicator for ImmunityBio?
ImmunityBio (IBRX) has a beta rating of -0.18. This means that it has an inverse relation to market volatility.